ArticleJournal for immunotherapy of cancer2022

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.

Carlos Gomez-Roca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.